Clinical Trial Update: Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on zanubrutinib combined with CAR T-cell therapy for recurrent or refractory aggressive B-cell non-Hodgkin lymphomas and transformed indole…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Diffuse Large B-cell Lymphoma Leg Type
• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation
• Ebv-positive Diffuse Large B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma with Myc Bcl2 and Bcl6 Rearrangements
• Intravascular Large B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CAR-T cell therapy
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Northwestern University | Conditions: Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Status: ACTIVE_NOT_RECRUITING